230 related articles for article (PubMed ID: 30917298)
41. Differential Profile of Primary and Recurrent Ameloblastomas Among Afro-descendants and Non-Afro-descendants-a Systematic Review.
Patel P; Effiom OA; Akinshipo AO; Akintoye SO
J Racial Ethn Health Disparities; 2024 Feb; 11(1):92-100. PubMed ID: 36596981
[TBL] [Abstract][Full Text] [Related]
42. Notch4 overexpression in ameloblastoma correlates with the solid/multicystic phenotype.
Siar CH; Nagatsuka H; Chuah KS; Rivera RS; Nakano K; Ng KH; Kawakami T
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Aug; 110(2):224-33. PubMed ID: 20659700
[TBL] [Abstract][Full Text] [Related]
43. Aberrant beta-catenin expression and adenomatous polyposis coli gene mutation in ameloblastoma and odontogenic carcinoma.
Siriwardena BS; Kudo Y; Ogawa I; Tilakaratne WM; Takata T
Oral Oncol; 2009 Feb; 45(2):103-8. PubMed ID: 18486530
[TBL] [Abstract][Full Text] [Related]
44. Elevated APOBEC mutational signatures implicate chronic injury in etiology of an aggressive head-and-neck squamous cell carcinoma: a case report.
Patel J; den Breems NY; Tuluc M; Johnson J; Curry JM; South AP; Cho RJ
J Med Case Rep; 2021 Apr; 15(1):252. PubMed ID: 33926553
[TBL] [Abstract][Full Text] [Related]
45. BRAF p.V600E Mutational Status Does Not Correlate with Biological Behavior in Conventional Ameloblastomas: A Disease-Free Survival Analysis.
Martins-de-Barros AV; da Costa Araújo FA; Faro TF; de Aquino AAT; Barbosa Neto AG; da Silva HAM; de Lima ELS; Muniz MTC; de Oliveira E Silva ED; de Vasconcelos Carvalho M
Head Neck Pathol; 2024 Mar; 18(1):23. PubMed ID: 38504068
[TBL] [Abstract][Full Text] [Related]
46. Effectiveness of molecular-targeted chemotherapy in ameloblastomas: A systematic review.
Yoithapprabhunath TR; Srichinthu KK; Gupta D; Singh D; Pasupuleti S; Nirmal RM
Indian J Dent Res; 2022; 33(3):323-331. PubMed ID: 36656197
[TBL] [Abstract][Full Text] [Related]
47. p53 gene status and expression of p53, MDM2, and p14 proteins in ameloblastomas.
Kumamoto H; Izutsu T; Ohki K; Takahashi N; Ooya K
J Oral Pathol Med; 2004 May; 33(5):292-9. PubMed ID: 15078490
[TBL] [Abstract][Full Text] [Related]
48. DNA damage response activation and cell cycle dysregulation in infiltrative ameloblastomas: A proposed model for ameloblastoma tumor evolution.
Diniz MG; Guimarães BVA; Pereira NB; de Menezes GHF; Gomes CC; Gomez RS
Exp Mol Pathol; 2017 Jun; 102(3):391-395. PubMed ID: 28454892
[No Abstract] [Full Text] [Related]
49. Hypermethylation of p16 tumor-suppressor gene in ameloblastic carcinoma, ameloblastoma, and dental follicles.
Khojasteh A; Khodayari A; Rahimi F; Ghaderian MH; Jafarian M; Nayebi A; Akbarzadeh Najar R; Tabatabayipanah A; Jahangirnia A
J Oral Maxillofac Surg; 2013 Jan; 71(1):62-5. PubMed ID: 22705216
[TBL] [Abstract][Full Text] [Related]
50. Ultra-frequent HRAS p.Q61R somatic mutation in canine acanthomatous ameloblastoma reveals pathogenic similarities with human ameloblastoma.
Peralta S; McCleary-Wheeler AL; Duhamel GE; Heikinheimo K; Grenier JK
Vet Comp Oncol; 2019 Sep; 17(3):439-445. PubMed ID: 31041834
[TBL] [Abstract][Full Text] [Related]
51. Mutational spectrum of tobacco associated oral squamous carcinoma and its therapeutic significance.
Batta N; Pandey M
World J Surg Oncol; 2019 Nov; 17(1):198. PubMed ID: 31775759
[TBL] [Abstract][Full Text] [Related]
52. Whole Exome Sequencing of
Shimura M; Nakashiro KI; Sawatani Y; Hasegawa T; Kamimura R; Izumi S; Komiyama Y; Fukumoto C; Yagisawa S; Yaguchi E; Hitomi-Koide M; Hyodo T; Uchida D; Kawamata H
In Vivo; 2020; 34(6):3233-3240. PubMed ID: 33144428
[TBL] [Abstract][Full Text] [Related]
53. [Molecular biological and immunohistochemical analysis of tp53 in human ameloblastomas].
Appel T; Gath R; Wernert N; Martini M; Bergé S
Mund Kiefer Gesichtschir; 2004 May; 8(3):167-72. PubMed ID: 15138854
[TBL] [Abstract][Full Text] [Related]
54. Genetic heterogeneity and enrichment of variants in DNA-repair genes in ameloblastoma.
Awotoye W; Whitt JC; Yoo B; Farooqi MS; Farrow EG; Allareddy V; Amendt BA; Rengasamy Venugopalan S
J Oral Pathol Med; 2023 Mar; 52(3):263-270. PubMed ID: 36715450
[TBL] [Abstract][Full Text] [Related]
55. Detection of MAPK/ERK pathway proteins and KRAS mutations in adenomatoid odontogenic tumors.
Bologna-Molina R; Ogawa I; Mosqueda-Taylor A; Takata T; Sánchez-Romero C; Villarroel-Dorrego M; Takeda Y; Mikami T
Oral Dis; 2019 Mar; 25(2):481-487. PubMed ID: 30294831
[TBL] [Abstract][Full Text] [Related]
56. Characteristics of mutations in the p53 gene in oral squamous cell carcinoma associated with betel quid chewing and cigarette smoking in Taiwanese.
Hsieh LL; Wang PF; Chen IH; Liao CT; Wang HM; Chen MC; Chang JT; Cheng AJ
Carcinogenesis; 2001 Sep; 22(9):1497-503. PubMed ID: 11532872
[TBL] [Abstract][Full Text] [Related]
57. Molecular pathogenesis of ameloblastoma.
Marín-Márquez C; Kirby J; Hunter KD
J Oral Pathol Med; 2024 May; 53(5):277-293. PubMed ID: 38664938
[TBL] [Abstract][Full Text] [Related]
58. Metastasising ameloblastoma or ameloblastic carcinoma? A case report with mutation analyses.
Hurník P; Putnová BM; Ševčíková T; Hrubá E; Putnová I; Škarda J; Havel M; Res O; Cvek J; Buchtová M; Štembírek J
BMC Oral Health; 2023 Aug; 23(1):563. PubMed ID: 37573343
[TBL] [Abstract][Full Text] [Related]
59. K-Ras gene status and expression of Ras/mitogen-activated protein kinase (MAPK) signaling molecules in ameloblastomas.
Kumamoto H; Takahashi N; Ooya K
J Oral Pathol Med; 2004 Jul; 33(6):360-7. PubMed ID: 15200485
[TBL] [Abstract][Full Text] [Related]
60. Ultra-deep targeted sequencing of advanced oral squamous cell carcinoma identifies a mutation-based prognostic gene signature.
Chen SJ; Liu H; Liao CT; Huang PJ; Huang Y; Hsu A; Tang P; Chang YS; Chen HC; Yen TC
Oncotarget; 2015 Jul; 6(20):18066-80. PubMed ID: 25980437
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
